Board summary
Key figures
61,233
Registered population
59.9% aged 18–64
17.1%
Aged 65+
ICB 14.9% · England 17.9%
49.4%
In IMD quintile 1
ICB 40.7% · England 21.0%
~26,274
Core20 residents (est.)
Resident basis; registered basis ~30,428 · see page 3
9,691
Hypertension register
+6.95% in 3 yrs · England +5.60%
742
SMI register
23.8% of Rochdale (LAD)'s
1,299
COPD register
Reviews +8.52% in 3 yrs
Forecast to 2030
11,206
Hypertension patients, 2030
+1,515 on today
77.5%
QRISK ≥20% on statins, 2030
+3.24pp over 3 yrs
4.4%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Unreviewed asthma cohort despite rapid three-year gain.
Annual asthma reviews rose +18.2% over 2023 to 2025 (England +4.4%) to 63.3% (England 65.7%), leaving about 1,600 patients unreviewed.
Age-five MMR drops between first and second doses.
In Q1 2025/26, age-five MMR coverage fell from 96.8% at dose 1 to 90.3% at dose 2, and by 16 pp at Ashworth Street.
High-risk statin cover exceeds England, unit cost higher.
Lipid-lowering therapy for QRISK ≥ 20% exceeds England (63.6%), though adult prescribing is 2,098 per 1,000 (England 4,100) and costs £23,764 more than England's.
Population, age and ethnicity
A list of 61,233 balances above-average youth shares with 10,504 older patients
Across 61,233 registered patients, 22.9% (14,047) are aged 0-17, compared to 23.5% in Rochdale (LAD), 21.8% in NHS Greater Manchester ICB, and 19.6% in England. Patients aged 65+ comprise 17.1% (10,504), above Rochdale (LAD) (14.7%) and the ICB (14.9%), but below England (17.9%). Practice youth shares range from 18.7% at Edenfield Road Surgery to 26.3% at Mark Street Surgery, with Ashworth Street Surgery at 23.3%. Gypsy or Irish Traveller and Roma groups each represent 0.1% of residents. Projected population growth to 2030 is 0.6% (methodology unverified). Registered list counts differ from resident Census bases.
Age profile
65+: ICB 14.9%, England 17.9%
Older people · falls rows are Rochdale (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Rochdale LA) | 2,300 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 78.2% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 55.2% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Rochdale LA) | 1,088 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Rochdale LA) | 19.0 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation affects 49.4% of patients, spanning a 91.4 pp spread across practices
The PCN Core20 cohort is 49.4%, above Rochdale (LAD) at 48.0%, NHS Greater Manchester Integrated Care Board at 40.7%, and England at 21.0%. Across practices, Core20 concentration spans a 91.4 pp range. Healey Surgery is at 8.6%. Inspire Medical Centre is at 100.0%. By volume, Ashworth Street Surgery carries 8,198 estimated Core20 patients at 48.6%. Practice-level registered estimates sum to 30,428, whereas estimated resident Core20 population is 26,274. Targeting must balance intense practice concentration against absolute patient volume.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
742
SMI register
1.18% recorded prevalence
393
Learning disability register
0.63% recorded prevalence
33
Care homes, 783 beds
In the PCN catchment
9.7%
Provide unpaid care
Rochdale (LAD), Census 2021
The PCN records 742 patients on the severe mental illness register (1.2% prevalence, England 1.0%) and 393 on the learning disability register (0.6%, England 0.6%). Catchment services include 33 care homes with 783 beds, though bed capacity does not establish registered resident numbers. Severe mental illness prevalence exceeding England (1.0%) indicates sustained capacity is needed for annual physical health checks.
Severe mental illness: physical health checks
SMI prevalence is 1.2% (England 1.0%). Recorded checks reached 82.3% for blood pressure (England 83.4%) and 82.5% for BMI (England 82.1%), with alcohol status at 81.7%. Tracking missing check elements separately is necessary to secure full physical reviews.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
9,691
Hypertension register
+6.95%
Register growth, 3 yrs
Rochdale (LAD) +6.17% · England +5.60%
+5.28pp
BP control, under 80
≤140/90 · +3.91pp aged 80+
+1,515
More patients by 2030
Forecast 11,206 (17.65%)
Hypertension case-finding and control
Hypertension recorded prevalence is 15.4% (9,691 patients), compared with 15.6% in Rochdale, 14.4% in the ICB, and 15.2% in England. Recent blood pressure recording reached 88.1%, trailing Rochdale (89.5%), the ICB (90.3%), and England (90.0%). For patients under 80, blood pressure control to <= 140/90 mmHg is 67.4% (England 67.8%, Rochdale 67.8%, ICB 68.6%), while overall treatment to target is 70.5% (England 70.3%). Observation periods and denominators were not captured. Trailing blood pressure recording and control rates may indicate recall gaps, which a clinical audit of uncontrolled patients could test.
Lipids and statins
Statin therapy reaches 70.6% for QRISK ≥ 20% (England 63.6%, Rochdale 68.3%) and 77.6% in CKD (England 70.3%), yet adult lipid-regulating prescribing is 2,098 items per 1,000 (England 4,100). Prescribing volume trailing England despite higher high-risk coverage could reflect differences in primary prevention initiation, which practice audits could verify.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 99,017 | £2.10 | £1.94 | £1.86 | £207,936 |
| Cardiovascular (all), 2025 | 122,191 | £4.10 | £3.15 | £3.33 | £500,983 |
In 2026, the PCN prescribed 99,017 lipid-regulating items at £2.10 per item, compared with £2.08 in Rochdale, £1.94 in the ICB, and £1.86 in England (£23,764 more than at England's unit cost). Higher unit cost than England may reflect formulary choices or dosing formulations, which a local prescribing audit could evaluate.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+18.18%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+0.68%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 7.5% (England 6.6%), with 5–19 asthma management prescribing at 1,941 per 1,000 (England 1,488). Annual asthma reviews rose +18.2% over 2023 to 2025 (England +4.4%) but stand at 63.3% (England 65.7%), leaving an estimated 1,611 patients without a recorded review. Second-hand smoke recording for ages 6–19 is 76.9% (Rochdale 81.6%), while COPD review coverage is 73.4% (England 76.4%). Below-comparator review rates alongside high youth prescribing suggest prioritising structured paediatric and adult respiratory reviews.
Cancer register and children's immunisation
In Q1 2025/26, 6-in-1 coverage at 12 months is 88.2% and MMR dose 1 at 24 months is 85.6%, both below the 95.0% target. At age 5, MMR dose 1 is 96.8%, but dose 2 is 90.3%—a 6.5 pp drop that reaches 16 pp at Ashworth Street Surgery. Cancer prevalence is 3.6% (England 3.8%). This dose drop-off could reflect second-dose recall gaps (unverified locally; a recall audit would test this).
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Greater Manchester ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,270
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Greater Manchester ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 15% | 2,193 |
| Prostate | 61.7% | 53.2% | 14% | 1,788 |
| Breast | 82.5% | 85.4% | 19% | 1,758 |
| Bowel | 46.3% | 47.0% | 19% | 1,427 |
| Skin cancer | 84.5% | 87.8% | 27% | 580 |
Early-stage diagnosis (stages 1 and 2) in NHS Greater Manchester ICB was 55.6% in 2022 (6,491 of 11,679 known-stage cancers; England 55.3%), with distance to the 75.0% national ambition by 2028 of -19.4 pp, and 70.8% having a known stage (11,679 of 16,492 registered cancers). Reaching 75% requires 2,268.2 extra early cases a year (about 2,270). Primary care screening uptake in women aged 25-49 is 63.7% (Rochdale 68.8%, England 66.8%) and changed -1.4% over 2023 to 2025, while breast screening aged 53 to 70 is 67.6% (England 69.9%). Screening gaps may contribute to delayed detection, so targeted practice recall is warranted.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In provisional Jul 2026, Northern Care Alliance NHS Foundation Trust achieved 78.6% on the 62-day referral to treatment standard (distance to the 85.0% standard: -6.4 pp), ahead of Manchester University NHS Foundation Trust (72.8%), Tameside and Glossop Integrated Care NHS Foundation Trust (76.8%), NHS Greater Manchester Integrated Care Board (75.7%), and England (71.2%). On the 28-day faster diagnosis standard, Northern Care Alliance reached 75.2% (distance to the 75.0% standard: 0.2 pp), trailing Manchester University (80.1%), Tameside and Glossop (82.5%), the ICB (79.5%), and England (79.3%). Trust delays could lengthen diagnostic intervals for PCN referrals.
| Pathways within standard (%) | Northern Care Alliance | Tameside and Glossop Integrated Care | Manchester | Greater Manchester ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 75.20 | 82.48 | 80.06 | 79.53 | 79.32 |
| 31-day treatment (96%) | 94.54 | 96.25 | 92.54 | 96.49 | 92.50 |
| 62-day referral to treatment (85%) | 78.65 | 76.77 | 72.85 | 75.73 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Northern Care Alliance | Tameside and Glossop Integrated Care | Manchester | England |
|---|---|---|---|---|
| MRI | 5.09 | 0.00 | 11.68 | 21.40 |
| CT | 4.10 | 0.18 | 14.66 | 9.92 |
| Echocardiography | 31.48 | 0.00 | 4.91 | 28.48 |
| Colonoscopy | 40.04 | 1.51 | 4.51 | 30.83 |
| Gastroscopy | 36.48 | 5.45 | 29.35 | 29.02 |
| All 15 DM01 tests | 15.71 | 0.80 | 8.98 | 23.14 |
| Community services activity | Rochdale residents | Greater Manchester ICB |
|---|---|---|
| Care contacts | 60,250 | 573,310 |
| Referrals | 9,455 | 94,470 |
| Patients with a contact | 19,345 | 183,535 |
Community services (residents of Rochdale), Jun 2026 (provisional). In provisional Jun 2026 community services data for Rochdale borough residents (wider system data, not PCN level), 24,650 of 60,250 community contacts were with adults aged 65 and over, representing a 40.9% share. This older-adult share reflects borough-wide community activity, but individual PCN patient volumes are not captured in this dataset.
Practice variation and patient experience
Inspire Medical Centre achieved 99.0% QOF clinical points alongside 100.0% Core20 share
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Ashworth Street | 133 | 48.6 | 52.5% | 78.5% | 84.4% |
| Yorkshire St | 99 | 66.3 | 58.0% | 83.3% | 80.8% |
| Dawes | 107 | 49.0 | 45.6% | 76.2% | 76.2% |
| Edenfield Road | 115 | 18.4 | 49.7% | 71.3% | 76.1% |
| Mark Street | 83 | 75.6 | 38.0% | 83.7% | 75.7% |
| Healey Surgery | 101 | 8.6 | 56.2% | 72.3% | 73.4% |
| Inspire | 75 | 100.0 | 40.7% | 76.3% | 63.9% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Three-year register growth trailed England across learning disability, stroke, and COPD
Over 2023 to 2025, three-year register growth trailed England in learning disability (+0.8% vs +5.4%), stroke (-0.8% vs +2.3%), and COPD (+0.1% vs +2.6%). Conversely, process reviews showed sharp gains: annual asthma reviews rose +18.2% (England +4.4%), while severe mental illness physical checks rose +10.5 pp for blood pressure (England +4.4 pp) and +15.1 pp for alcohol status (England +5.4 pp). Non-frail diabetes HbA1c control improved +10.2% (England +4.4%) but remains at 55.2% (England 57.4%). Slower register growth could reflect case-finding variation, which local coding audits could clarify.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Learning disability register
Stroke register
COPD register
QRISK statin treatment
Diabetes statin (CVD)
Asthma reviews
Alcohol record (psychosis)
BP check (SMI)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Rochdale (LAD) | Asset | PCN | Rochdale (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 33 (783 beds) | n/a | Schools (catchment) | 109 | n/a |
| Children's centres | 8 | 17 | Places of worship | 60 | 116 |
| Libraries | 3 | 12 | Primary schools (LA maintained) | 14 | 38 |
| Primary academies | 14 | 26 | Special schools | 1 | 2 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma review recall
Asthma review coverage is 63.3% (England 65.7%, Rochdale 66.2%) across 4,387 registered patients, leaving an estimated 1,611 (about 1,600) patients without a recorded review in 12 months. For discussion: the PCN could run structured recall using a single review template, prioritising high-prescribing youth cohorts and after-school slots. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Age-five MMR second-dose recall
In Q1 2025/26, age-5 MMR coverage drops 6.5 pp from dose 1 (96.8%) to dose 2 (90.3%, below the 95.0% target by 4.7 pp) across 186 children, and 16 pp at Ashworth Street Surgery. For discussion: practices could audit age-five cohorts for missing second doses and offer catch-up slots. Low cost, quick to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Option 3
Heart failure and CVD coding audit
Heart failure prevalence is 1.0% (613 patients) against 1.1% in England and 1.2% in Rochdale, giving an unadjusted benchmark range of +59 to +104 patients across the 61,233 list. For discussion: practices could search records for cardiovascular medicines or discharge codes lacking a heart failure or stroke register entry. Low cost, quick to run.
Evidence base: the stroke/TIA register is the cohort for AF anticoagulation and blood-pressure control (pre-stroke prevention) as well as hyperacute care; practices well below expected prevalence are the case-finding list, and the pre-stroke prevention gap concentrates in deprived practices.
Policy anchor: Core20PLUS5 (CVD); NHS CVD ambitions to 2029.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Paediatric acute demand alignment (p2) | Aged 0-17 | Medium Term Planning Framework 2026 · Neighbourhood health framework | PCN |
| Dual track Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical health check recall (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension recall and titration (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Preschool MMR second dose recall (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall outreach (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Option 1 · Structured asthma review recall (p12) | Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · Age-five MMR second-dose recall (p12) | MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Option 3 · Heart failure and CVD coding audit (p12) | Registered population · Heart failure register · Heart Failure: QOF prevalence | Core20PLUS5 CVD · CVDPREVENT · SSNAP | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
